First, given that angiogenic factors, including vascular endothelial growth factor (VEGF), have been found to be important in the pathogenesis of leiomyoma [24], Chhabra et al. recently reported a prolonged response with bevacizumab in a patient with BML [25]. The gene discussed is VEGFA; the disease is leiomyoma.